|Bid||107.45 x 1100|
|Ask||107.39 x 1000|
|Day's Range||106.87 - 110.13|
|52 Week Range||80.24 - 140.36|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||82.40|
|Earnings Date||Feb 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||144.57|
With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.
Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.
Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.
IDEXX (IDXX) upgrades veterinary care experience by launching a rapid digital cytology service, thus enabling the provision of faster results.
Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has purchased the technology underlying the TEG® 6s Hemostasis Analyzer System from CoraMed Technologies, LLC. With this transaction, Haemonetics has acquired ownership of intellectual property previously licensed from CoraMed on an exclusive basis in the field of hospitals and hospital laboratories. By acquiring the underlying intellectual property, Haemonetics will now be able to pursue site of care opportunities beyond the hospital setting.
Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.
Medtronic's (MDT) Percept PC neurostimulator DBS system, with BrainSense technology, receives the CE Mark, thus clearing the way for the treatment of various neurologic disorders in the EU.
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Chief Executive Officer (CEO), John Sperzel, has promoted Tony Pare to the newly created position of Chief Commercial Officer (CCO), effective immediately. Mr. Pare previously served as Vice President and General Manager – International at T2 Biosystems. “I am delighted to appoint Tony as our CCO and look forward to working with him to expand our commercial success,” said Mr. Sperzel.